Mervyn Bibb

Cancer Targeting Systems, Inc. offers cancer care. The firm focuses on delivering cancer theranostic products combining imaging with therapy. The company was founded by Martin Pomper and Will West and is headquartered in Boston, MA.

Procter & Gamble Ltd. manufactures and markets consumer products. It provides fabric and home care products which include laundry, cleaning, detergents, soaps, softeners, and cleansers. The company was founded in 1837 and is located in Newcastle, UK.

RWC Partners Ltd. provides investment advisory services. Its activities portfolio include convertible bonds, European equity, Japan active engagement, equity income, emerging and frontier market equity, and global horizon equity. The company was founded by Chris Simon Maude, John Hugh Innes, and Mark Robert Hadsley-Chaplin in 2000 and is headquartered in London, the United Kingdom.

James Hutton Ltd. provides agricultural support activities. The company offers pathogen testing, plant analysis, and consulting services. It works with companies interested in licensing technologies that the researchers use to come up with a variety of potatoes, soft fruits, barley, and other agricultural products. The company was founded in 1989 and is headquartered in Dundee, the United Kingdom.

CellFactors Plc develops therapeutic products derived from human cells. The private company is based in Babraham, UK.

Biotechnology & Biological Sciences Research Council operates a funding agency for academic research and training. It funds bioscience, people and research infrastructure that helps to tackle major challenges such as the impact of climate change, a healthier old age, and sustainable food production, land use and energy production. The company is headquartered in Swindon, the United Kingdom.

CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

Velcourt Ltd. manages and advises on farms throughout Europe. The firm is retained by landowners, tenants, working farmers and institutional investors. The company was founded in 1967 and is headqaurtered in Ledbury, The United Kingdom.

Part of John Innes Centre Ltd., John Innes Foundation is a charity founded in 1910 and based in Norwich, UK. The foundation is dedicated to advancing plant science, horticulture, and related subjects. The British company provides substantial support to the rotation PhD programme at the John Innes Centre and the Sainsbury Laboratory, which is renowned for its academic excellence and groundbreaking research attracting elite candidates from around the world. The company achieves this by supporting scientific research, education, training, and public engagement, as well as maintaining and exploiting a unique historical collection of books and other documents. The foundation's mission is to advance the acquisition and application of knowledge about plants and microbes for societal, environmental, and commercial benefit.

RWC Asset Management LLP (RWC) is the alternative asset management subsidiary of RWC Partners Ltd. in Great Britain. The firm was founded by John H. Innes in 2007 as MPC Asset Management LLP. Headquartered in London, RWC primarily provides discretionary investment advisory services to pooled investment vehicles as well as separately managed accounts.

The James Hutton Institute engages in conducting research in environment, crop and food sciences. The firm focuses on crops, soils and land use and environmental research, and makes a contribution to the understanding of key global issues, such as food, energy and environmental security, and developing and promoting technological and management solutions. The company was founded on April 1, 2011 and is headquartered in Scotland, the United Kingdom.

PlaqueTec Ltd. develops a liquid biopsy system platform technology that provides unparalleled resolution of the biological processes that cause coronary artery disease. The firm’s Liquid Biopsy System addresses the underlying biomarker collection problems preventing advances in CAD research. The company was founded by Stephen Blatcher in 2000 and is headquartered in Cambridge, the United Kingdom.

The Aerospace Technology Institute (ATI) is a UK-based organization that creates technology strategies for the aerospace sector and funds research and development projects. The ATI is committed to managing and maintaining the UK Aerospace Technology Strategy and its associated funding streams. The private company is based in London, UK, and was founded in 2014. The British company has developed various tools, databases, and reports to support the aerospace industry. The ATI promotes transformative technology in air transport and funds world-class research and development. Gary Elliott has been the CEO of the company since 2014.

Cell Capital Partners LLP (Cell Capital) is a venture capital firm founded in 2020. The firm is headquartered in London, the United Kingdom.

Cyted Ltd. provides digital diagnostic infrastructure to know the early detection of cancer. The company was founded by Marcel Gehrung, Rebecca Fitzgerald, and Maria O'Donovan and is headquartered in Cambridge, the United Kingdom.

VaxEquity Ltd. is a UK biotechnology company founded in 2020 by Professor Robin Shattock, the head of immunology of infection at Imperial College and Morningside. The company is based in Little Chesterford, UK. The British company is developing transformative RNA therapeutics and vaccines using its next-generation self-amplifying RNA platform called SARNA. The platform provides extended duration of protein expression, enabling lower doses to be used for vaccines and higher protein levels to be achieved for therapeutics. VaxEquity is pioneering a next-generation approach by modifying its SARNA to modulate the innate immune response and thereby overcoming current limitations. The flexibility of the company's platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale.